ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.884,75
-0,57%
S&P 500
5.930,85
1,09%
Dow Jones
42.840,26
1,18%
Euro vs US Dollar
1,043
0,00%
Bitcoin
96.981,38
-0,22%
Pepperstone
Advertisement
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Theravance Biopharma Inc (TBPH)

  7. Theravance Biopharma Inc (TBPH) News

TBPH

Theravance Biopharma (TBPH)

Theravance Biopharma Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:TBPH
DatumZeitQuelleÜberschriftSymbolFirma
17/12/202412h00PR Newswire (US)Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 43rd Annual Healthcare ConferenceNASDAQ:TBPHTheravance Biopharma Inc
23/11/202400h09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TBPHTheravance Biopharma Inc
23/11/202400h08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TBPHTheravance Biopharma Inc
23/11/202400h06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TBPHTheravance Biopharma Inc
23/11/202400h04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TBPHTheravance Biopharma Inc
20/11/202412h00PR Newswire (US)Theravance Biopharma to Participate in an Upcoming Investor ConferenceNASDAQ:TBPHTheravance Biopharma Inc
14/11/202415h53Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:TBPHTheravance Biopharma Inc
14/11/202412h06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TBPHTheravance Biopharma Inc
14/11/202402h42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TBPHTheravance Biopharma Inc
12/11/202422h08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TBPHTheravance Biopharma Inc
12/11/202422h05PR Newswire (US)Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder ValueNASDAQ:TBPHTheravance Biopharma Inc
24/10/202422h44Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:TBPHTheravance Biopharma Inc
24/10/202412h00PR Newswire (US)Theravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024NASDAQ:TBPHTheravance Biopharma Inc
18/10/202415h00PR Newswire (US)Theravance Announces Publication of YUPELRI® (revefenacin) Area Under the Curve Spirometry Analysis in the International Journal of Chronic Obstructive Pulmonary DiseaseNASDAQ:TBPHTheravance Biopharma Inc
23/09/202412h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TBPHTheravance Biopharma Inc
10/09/202412h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TBPHTheravance Biopharma Inc
27/08/202412h00PR Newswire (US)Theravance Biopharma to Participate in an Upcoming Investor ConferenceNASDAQ:TBPHTheravance Biopharma Inc
23/08/202402h07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TBPHTheravance Biopharma Inc
23/08/202402h06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TBPHTheravance Biopharma Inc
23/08/202402h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TBPHTheravance Biopharma Inc
23/08/202402h03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TBPHTheravance Biopharma Inc
10/08/202400h02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TBPHTheravance Biopharma Inc
08/08/202422h57Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TBPHTheravance Biopharma Inc
05/08/202422h16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TBPHTheravance Biopharma Inc
05/08/202422h05PR Newswire (US)Theravance Biopharma, Inc. Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:TBPHTheravance Biopharma Inc
25/07/202412h00PR Newswire (US)Theravance Biopharma to Participate in an Upcoming Investor ConferenceNASDAQ:TBPHTheravance Biopharma Inc
22/07/202412h00PR Newswire (US)Theravance Biopharma to Report Second Quarter 2024 Financial Results on August 5, 2024NASDAQ:TBPHTheravance Biopharma Inc
13/07/202400h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TBPHTheravance Biopharma Inc
11/06/202422h17Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:TBPHTheravance Biopharma Inc
23/05/202400h08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TBPHTheravance Biopharma Inc
 Showing the most relevant articles for your search:NASDAQ:TBPH

Kürzlich von Ihnen besucht

NASDAQ
MSFT
Microsoft
USOTC
DTEGY
Deutsche Telekom (QX)
NYSE
KO
Coca Cola
CCOM
US500
US 500
COIN
ETHUSD
Ethereum
AMEX
SPY
SPDR S&P 500
NYSE
JPM
JP Morgan Chase
TG
CBK
Commerzbank
TG
ALV
Allianz
TG
BAYN
Bayer
CCOM
SILVER
SILVER
NASDAQ
AMZN
Amazon.com
TG
NOV
Novo Nordisk
NASDAQ
TSLA
Tesla
NASDAQ
GOOGL
Alphabet
FX
EURJPY
Euro vs Yen
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten